Pfizer Inc. $PFE Shares Sold by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 781,802 shares of the biopharmaceutical company’s stock after selling 28,168 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Pfizer were worth $22,297,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Retirement Wealth Solutions LLC raised its position in Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 509 shares in the last quarter. Evolution Wealth Management Inc. boosted its position in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Keb Asset Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $26,000. Field & Main Bank acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $27,000. Finally, Global Trust Asset Management LLC increased its holdings in shares of Pfizer by 126.7% during the 1st quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 650 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.8%

Pfizer stock opened at $29.80 on Tuesday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The stock has a market capitalization of $169.82 billion, a PE ratio of 39.20, a price-to-earnings-growth ratio of 2.04 and a beta of 0.32. The business has a 50 day simple moving average of $28.30 and a 200-day simple moving average of $26.67. Pfizer Inc. has a 12 month low of $23.62 and a 12 month high of $30.44.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm posted $0.78 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.8%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is 226.32%.

Analyst Ratings Changes

Several equities analysts recently issued reports on PFE shares. Cantor Fitzgerald boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 9th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.72.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded approval of TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for men with metastatic hormone-sensitive prostate cancer whose tumors have homologous recombination repair (HRR) gene mutations, including BRCA and non-BRCA mutations. Moving the treatment into an earlier stage of metastatic disease could enlarge the addressable patient population and support future sales growth. Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
• Positive Sentiment: Pfizer also reported Phase 2 results across serotypes for its 25-valent pneumococcal conjugate vaccine candidate, 25vPnC. The update adds visibility to the company’s vaccine pipeline, though the available report does not provide enough detail to assess the results’ commercial significance. Pfizer announces results across serotypes in Phase 2 study of 25vPnC
• Neutral Sentiment: Pfizer’s shares have gained about 29.7% over the past year and are near their 52-week high, prompting discussion over whether the valuation is ahead of the company’s earnings growth. Investors may require further pipeline or operating improvements to justify additional gains. Pfizer Stock Looks Above Fair Value As 30% Run Continues
• Neutral Sentiment: Pfizer was relatively resilient while Moderna and BioNTech declined amid disappointment over cancer-vaccine trial data. The comparison may offer some support for PFE, but it does not directly change Pfizer’s fundamentals. Moderna Tumbles as Cancer Vaccine Selloff Deepens
• Negative Sentiment: Broader healthcare stocks traded lower, creating sector-level pressure on Pfizer. Separately, an experimental Pfizer lung-cancer drug showed a survival benefit in some patients despite a failed trial, leaving its development outlook uncertain rather than providing a clear catalyst. Healthcare Stocks Softer Monday

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.